Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy

Recent type 2 diabetes guidance from the UK’s National Institute for Health and Care Excellence (NICE) proposes offering SGLT2-inhibitor therapy to people with established atherosclerotic cardiovascular disease (ASCVD) or heart failure, and considering SGLT2-inhibitor therapy for those at high-risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, Katherine G., Hopkins, Rhian, Shields, Beverley M., Thomas, Nicholas J., McGovern, Andrew P., Dennis, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623735/
https://www.ncbi.nlm.nih.gov/pubmed/37919773
http://dx.doi.org/10.1186/s12933-023-02032-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623735/
https://www.ncbi.nlm.nih.gov/pubmed/37919773
http://dx.doi.org/10.1186/s12933-023-02032-x

Ejemplares similares